Back to search

Aristotle University Of Thessaloniki (AUTH)

Κινητοποίηση των αρχέγονων αιμοποιητικών κυττάρων και κινητική εμφύτευσης: προεκτάσεις για τη γονιδιακή θεραπεία της θαλασσαιμίας

Abstract

dc:description

High numbers of genetically modified hematopoietic stem cells (HSCs) equipped with enhanced engrafting potential are required for successful gene therapy of thalassemia. We investigated the mobilization with G-CSF, Plerixafor or Plerixafor+G-CSF, in thalassemic, Hbbth3/45.2+ mice in terms of safety and efficacy, as well as the engraftment kinetics of the mobilized cells after competitive primary and noncompetitive secondary transplantation and transducibility of the differently mobilized cells. There was no death or clinical sequelae of splenic rupture in G-CSF-, Plerixafor- or Plerixafor+G-CSF-treated animals of normal or thalassemic strain, however, hemorrhagic infarcts in the spleen were detected all thalassemic mobilization groups. HBBth-3 mice mobilized less effectively than C57Bl6 mice with G-CSF, due to increased splenic trapping of hematopoietic stem and progenitor cells. Splenectomy restored the mobilization proficiency of thalassemic mice at comparable levels to normal mice and resulted in the development of a hematopoietic compensatory mechanism in the thalassemic liver. Plerixafor- alone mobilizes in comparable levels with G-CSF, whereas Plerixafor+G-CSF-mobilization resulted in higher stem and progenitor cell yields compared to G-CSF- or Plerixafor-alone. Plerixafor+G-CSF-mobilized Hbbth3/45.2+cells achieved faster hematologic reconstitution and higher levels of donor chimerism over all other types of mobilized cells, after competitive transplantation to B6.BoyJ /45.1+recipients. Moreover, secondary G-CSF- or Plerixafor+G-CSF- secondary recipients presented stable or even higher levels of chimerism, in contrast to the lower donor chimerism of mice that underwent transplantation from Plerixafor-bone marrow chimeras. Plerixafor-mobilized cells showed decreased competiveness over G-CSF- or Plerixafor+G-CSF cells, a finding associated with the mobilization of more actively proliferating cells and higher c-kit+ CD26 expression. Both differently mobilized and steady state hematopoietic progenitors represented a high transduction efficacy when transduced with a GFP reporter lentiviaral vector, with Plerixafor-mobilized cells achieving a more constant GFP expression. Overall, Plerixafor+G-CSF-mobilized blood represents an optimal graft for thalassemia gene therapy because of the higher HSC yields, the faster hematological recovery, the superiority in long-term engraftment over single-agent-mobilized blood cells and the high transduction capacity.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Psatha, Nikoleta
  • Ψαθά, Νικολέτα

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/37325

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Psatha, Nikoleta; Ψαθά, Νικολέτα. Κινητοποίηση των αρχέγονων αιμοποιητικών κυττάρων και κινητική εμφύτευσης: προεκτάσεις για τη γονιδιακή θεραπεία της θαλασσαιμίας. Aristotle University Of Thessaloniki (AUTH), 2013. http://hdl.handle.net/10442/hedi/37325